KBC Group NV Has $42,000 Stake in GRAIL, Inc. $GRAL

KBC Group NV lessened its stake in shares of GRAIL, Inc. (NASDAQ:GRAL) by 42.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 818 shares of the company’s stock after selling 612 shares during the period. KBC Group NV’s holdings in GRAIL were worth $42,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Wealthquest Corp bought a new stake in GRAIL in the first quarter valued at $18,247,000. AQR Capital Management LLC grew its stake in shares of GRAIL by 61.0% in the 1st quarter. AQR Capital Management LLC now owns 1,337,163 shares of the company’s stock valued at $33,991,000 after buying an additional 506,440 shares during the period. Carnegie Investment Counsel bought a new stake in GRAIL in the 2nd quarter valued at about $8,520,000. Allianz Asset Management GmbH acquired a new position in GRAIL during the 2nd quarter worth approximately $6,164,000. Finally, Pier Capital LLC acquired a new position in GRAIL during the 2nd quarter worth approximately $5,538,000.

Insider Buying and Selling at GRAIL

In other news, President Joshua J. Ofman sold 6,114 shares of GRAIL stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $82.01, for a total transaction of $501,409.14. Following the sale, the president directly owned 381,818 shares in the company, valued at $31,312,894.18. The trade was a 1.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert P. Ragusa sold 7,239 shares of the business’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $68.88, for a total transaction of $498,622.32. Following the completion of the transaction, the chief executive officer directly owned 727,388 shares in the company, valued at $50,102,485.44. This trade represents a 0.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 113,295 shares of company stock valued at $7,380,888. Insiders own 1.85% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Guggenheim upgraded GRAIL from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Wednesday, November 12th. UBS Group set a $75.00 price target on shares of GRAIL in a research report on Friday, October 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group raised their price objective on shares of GRAIL from $85.00 to $105.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $75.00.

GRAIL Stock Performance

NASDAQ:GRAL opened at $110.16 on Thursday. GRAIL, Inc. has a 52 week low of $16.10 and a 52 week high of $115.76. The firm has a 50-day moving average price of $76.05 and a two-hundred day moving average price of $51.69. The firm has a market cap of $4.29 billion, a price-to-earnings ratio of -9.47 and a beta of 4.31.

GRAIL (NASDAQ:GRAL) last released its earnings results on Wednesday, November 12th. The company reported ($2.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.40) by $0.94. The company had revenue of $36.19 million during the quarter, compared to analyst estimates of $33.83 million. GRAIL had a negative return on equity of 15.69% and a negative net margin of 286.43%. As a group, sell-side analysts forecast that GRAIL, Inc. will post -15.15 earnings per share for the current year.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.